Ontology highlight
ABSTRACT: Background
Oral testosterone undecanoate (TU) formulations may provide effective, safe, and easily titratable testosterone replacement therapy.Objective
Demonstrate efficacy and safety of a novel oral TU formulation.Design
An open-label, single-arm, multi-center trial treated 155 hypogonadal men for 180 days. Treatment began at 200 mg TU twice daily with meals; doses were titrated over two 28-day cycles to between 100 and 800 mg TU daily, measuring average testosterone (T Cavg) after 90 days. Ambulatory blood pressure monitoring (ABPM) occurred at baseline, 120, and 180 days.Methods
Titrations used a randomized blood sample taken 3-, 4-, or 5-h post-morning dose. Outcomes used sodium fluoride/ethylenediaminetetraacetate plasma testosterone (T) val
SUBMITTER: Bernstein JS
PROVIDER: S-EPMC11008350 | biostudies-literature | 2024 Jan-Dec
REPOSITORIES: biostudies-literature